HEMOGENYX PHARMACEUTICALS PLC

08401609
Active London

Research and experimental development on biotechnology

16 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
H

HEMOGENYX PHARMACEUTICALS PLC

08401609

Research and experimental development on biotechnology

Founded 13 Feb 2013 Active London, England 16 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology

Previous Company Names

SILVER FALCON PLC 25 Nov 2014 — 4 Oct 2017
SILVER FALCON LIMITED 13 Feb 2013 — 25 Nov 2014
Accounts Submitted 16 May 2026 Next due 30 Jun 2026 5 days overdue
Confirmation Submitted 3 Mar 2026 Next due 27 Feb 2027 7 months remaining
Net assets £1M £291K 2025 year on year
Total assets £4M £36K 2025 year on year
Total Liabilities £3M £327K 2025 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

6 Heddon Street London W1B 4BT England

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for HEMOGENYX PHARMACEUTICALS PLC (08401609), an active life sciences and medical technology company based in London, England. Incorporated 13 Feb 2013. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2025
Type group
Next accounts 31 Dec 2025
Due by 30 Jun 2026 1 month overdue

Balance Sheet & P&L (2014–2025)

Cash in Bank

£1.59M

Increased by £1.43M (+897%)

Net Assets

£1.14M

Increased by £291.00k (+34%)

Total Liabilities

£3.03M

Decreased by £327.00k (-10%)

Turnover

£7.00k

Employees

16

Debt Ratio

73%

Decreased by 7 (-9%)

Financial History

Revenue, profit, EBITDA and key financial figures

2025
31 Dec Year End
2024
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 7

Investors (3)

Investor NameInvestor SinceParticipating Rounds
Investor 3Nov 2020IPO
Investor 2Sept 2023IPO
Investor 1Nov 2024IPO

Share Capital

Share Capital

Share allotments and capital structure

36 Allotments 1,320,917,192 Shares £2926125722.80m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
27 Apr 2026374,532£3.00m£8.01
18 Feb 202615,952£56k£3.5
18 Feb 202634,889£63k£1.8
13 Feb 2026333,333£2.50m£7.5
16 Dec 202511,821£104k£8.84

Officers

Officers

0 active 3 resigned
Status

No officers found

No officers found

Shareholders

Shareholders (3)

Alexis Sandler
5.6%
Vladislav Sandler
3.1%

Persons with Significant Control

Persons with Significant Control (0)

0 Active 2 Ceased

Vladislav Sandler

Ceased 4 Oct 2018

Ceased

Alexis Sandler

Ceased 4 Oct 2018

Ceased

Group Structure

Group Structure

HEMOGENYX PHARMACEUTICALS PLC Current Company
HEMOGENYX UK LIMITED united kingdom

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
16 May 2026AccountsAnnual accounts made up to 31 Dec 2025
16 May 2026AccountsAnnual accounts made up to 31 Dec 2025
8 May 2026CapitalAllotment of shares (GBP 14,051,114.0903) on 27 Apr 2026
3 Mar 2026Confirmation StatementConfirmation statement made on 13 Feb 2026 with no updates
27 Feb 2026CapitalAllotment of shares (GBP 14,047,368.7703) on 18 Feb 2026
16 May 2026 Accounts

Annual accounts made up to 31 Dec 2025

16 May 2026 Accounts

Annual accounts made up to 31 Dec 2025

8 May 2026 Capital

Allotment of shares (GBP 14,051,114.0903) on 27 Apr 2026

3 Mar 2026 Confirmation Statement

Confirmation statement made on 13 Feb 2026 with no updates

27 Feb 2026 Capital

Allotment of shares (GBP 14,047,368.7703) on 18 Feb 2026

Recent Activity

Latest Activity

Annual accounts made up to 31 Dec 2025

1 months ago on 16 May 2026

Annual accounts made up to 31 Dec 2025

1 months ago on 16 May 2026

Allotment of shares (GBP 14,051,114.0903) on 27 Apr 2026

1 months ago on 8 May 2026

Confirmation statement made on 13 Feb 2026 with no updates

4 months ago on 3 Mar 2026

Allotment of shares (GBP 14,047,368.7703) on 18 Feb 2026

4 months ago on 27 Feb 2026